GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Ending Cash Position

Biogen (MEX:BIIB) Ending Cash Position : MXN53,157 Mil (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Biogen Ending Cash Position?

Biogen's Ending Cash Position for the quarter that ended in Mar. 2025 was MXN53,157 Mil.

Biogen's quarterly Ending Cash Position increased from Sep. 2024 (MXN33,458 Mil) to Dec. 2024 (MXN49,532 Mil) and increased from Dec. 2024 (MXN49,532 Mil) to Mar. 2025 (MXN53,157 Mil).

Biogen's annual Ending Cash Position declined from Dec. 2022 (MXN66,663 Mil) to Dec. 2023 (MXN17,821 Mil) but then increased from Dec. 2023 (MXN17,821 Mil) to Dec. 2024 (MXN49,532 Mil).

Biogen Ending Cash Position Historical Data

The historical data trend for Biogen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Ending Cash Position Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26,480.23 46,390.36 66,662.67 17,821.26 49,532.29

Biogen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17,831.02 34,971.25 33,457.76 49,532.29 53,156.54

Biogen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Biogen's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=21896.399+27635.888
=49,532

Biogen's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=48588.226+4568.315
=53,157

Biogen Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Biogen's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Ending Cash Position
Comparable Companies
OGN AMRN MDCX SCLX MIRA LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN GILD PFE XPAR:SAN BMY TSE:4519 LSE:GSK
Traded in Other Exchanges
BIIB:USA 1BIIB:Italy 0R1B:UK IDP:Germany IDP:Germany IDP:Germany IDP:Germany BIIB:Chile BIIB34:Brazil BIIB:Austria BIIB:Argentina
Address
225 Binney Street, Cambridge, MA, USA, 02142
Website
https://www.biogen.com
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.